Kelvin Kinuthia Reacts To FDA Blindness Warning On Ozempic Surgery

Kelvin Kinuthia Reacts To FDA Blindness Warning On Ozempic Surgery

Kenyan digital content creator Kelvin Kinuthia has reacted humorously to a new safety alert issued to users of popular weight-loss injections, including Ozempic and Mounjaro, over a rare eye condition linked to permanent vision loss.

Responding to a social media post detailing the advisory from the United States Food and Drug Administration (FDA), Kinuthia made light of the health warning with a witty remark.

“Eeiiyy nionge kwa kusimama ama kwa kuketi,” Kinuthia commented, sparking immediate engagement from followers familiar with his public weight-loss transformation.

Kinuthia’s reaction drew widespread attention because he has openly documented his use of medical procedures and injectable treatments to shed weight over the past several years. On October 20, 2026, the creator shared before-and-after photos comparing his physique from October 2023 to October 2026, revealing that his weight had dropped from 148kg to 112kg.

Crediting local clinic Nure Aesthetics for supporting his recent progress, Kinuthia disclosed on October 5, 2026, that Mounjaro injections helped him lose 10kg within a single month, bringing him down from 125kg to 115kg. Prior to Mounjaro, he documented losing 5kg during his first week on Ozempic shots in May 2025, following an earlier gastric balloon procedure in 2022.

The FDA has instructed manufacturers of popular GLP-1 medications—including Ozempic, Wegovy, Mounjaro, and Zepbound—to update their safety labels to warn patients about nonarteritic…

In brief

Kenyan digital content creator Kelvin Kinuthia has reacted humorously to a new safety alert issued to users of popular weight-loss injections, including Ozempic and Mounjaro, over a rare eye condition linked to permanent vision loss. “Eeiiyy nionge kwa kusimama ama kwa kuketi,” Kinuthia commented, sparking immediate engagement from followers familiar with his public weight-loss transformation.

This is the opening of the story, shared with credit to Ghafla!. The rest of the report — with every detail — continues on the publisher’s website.

Continue reading at Ghafla! ↗

Cookie settings

Choose which cookies we may use. You can change this at any time from Cookie settings in the footer. Details of each cookie are in the Cookie Policy.

Strictly necessary

Needed for sign-in, security, payments and remembering these choices. Always on.

Preferences

Remember settings such as dark mode.

Analytics & performance

Help us count visits, understand which pages, devices and countries our readers use, and measure how well the site performs – anonymous and aggregated.

Advertising & marketing

Lets advertising partners show and personalise adverts, measure impressions, clicks and visits, prevent ad fraud and pay us – this is how the free site is funded.

🔔 News notifications

Get headlines from NewsHub on this device — even when the site is closed.

You can switch this off at any time. Works on Android, Windows, Mac and Linux browsers; on iPhone/iPad add the site to your Home Screen first.